Overview
SCIENTIFIC SCORE
Possibly Effective
Based on 4 Researches
7.5
USERS' SCORE
Good
Based on 4 Reviews
8.2
Supplement Facts
Serving Size: 1 Capsule
Amount Per Serving
%DV
N-acetyl-L-cysteine
600 mg
**
Top Medical Research Studies
9
We examined how N-acetyl-L-cysteine (NAC) impacts lung health in the context of chronic obstructive pulmonary disease (COPD) by exposing rats to cigarette smoke (CS) over a four-week period. This study set up a model of lung injury to assess the damage caused by CS and the protective effects of NAC.
After exposure, we observed significant changes in the lung tissue, including widening of the alveolar walls and increased inflammatory cell infiltration, suggesting serious oxidative injury. We found that NAC treatment helped counteract some of the harmful effects, reducing markers of oxidative stress like malondialdehyde while boosting protective enzymes such as superoxide dismutase.
Additionally, we noted that in lung cells exposed to cigarette smoke, NAC also mitigated apoptosis, which is a form of programmed cell death induced by oxidative stress. This underscores the potential for NAC as a therapeutic agent to replenish the body’s glutathione and aid in protecting lung health amidst the damaging effects of smoking.
Overall, our findings point to NAC's beneficial role in shielding lung tissues from damage due to cigarette smoke, reinforcing its use as an antioxidant in managing COPD.
After exposure, we observed significant changes in the lung tissue, including widening of the alveolar walls and increased inflammatory cell infiltration, suggesting serious oxidative injury. We found that NAC treatment helped counteract some of the harmful effects, reducing markers of oxidative stress like malondialdehyde while boosting protective enzymes such as superoxide dismutase.
Additionally, we noted that in lung cells exposed to cigarette smoke, NAC also mitigated apoptosis, which is a form of programmed cell death induced by oxidative stress. This underscores the potential for NAC as a therapeutic agent to replenish the body’s glutathione and aid in protecting lung health amidst the damaging effects of smoking.
Overall, our findings point to NAC's beneficial role in shielding lung tissues from damage due to cigarette smoke, reinforcing its use as an antioxidant in managing COPD.
7
We explored the role of mucus hypersecretion in chronic obstructive pulmonary disease (COPD), which is a common trait tied to worse health outcomes. Notably, this mucus issue can sometimes arise before any noticeable airway obstruction, prompting us to consider early interventions as a way to prevent further complications.
Our review delved into the effectiveness of N-acetylcysteine (NAC), a treatment that shows promise in improving mucus clearance and reducing harmful protein expressions related to mucus. NAC operates through antioxidant mechanisms, both directly and indirectly, and it intervenes in inflammation by targeting specific pathways in airway cells. It helps inhibit certain factors responsible for inflammation and can lower levels of certain harmful cytokines.
Through various clinical experiences, it appears that using NAC as an add-on therapy can help alleviate symptoms and enhance the overall well-being of COPD patients. Thus, we conclude that NAC may serve as a worthy candidate for the early treatment of individuals at risk of developing COPD.
Our review delved into the effectiveness of N-acetylcysteine (NAC), a treatment that shows promise in improving mucus clearance and reducing harmful protein expressions related to mucus. NAC operates through antioxidant mechanisms, both directly and indirectly, and it intervenes in inflammation by targeting specific pathways in airway cells. It helps inhibit certain factors responsible for inflammation and can lower levels of certain harmful cytokines.
Through various clinical experiences, it appears that using NAC as an add-on therapy can help alleviate symptoms and enhance the overall well-being of COPD patients. Thus, we conclude that NAC may serve as a worthy candidate for the early treatment of individuals at risk of developing COPD.
7
We set out to understand the impact of N-acetyl-L-cysteine (NAC) on chronic obstructive pulmonary disease (COPD) by examining its effects in a study involving COPD mice. These mice were divided into groups, where some received NAC while others were given a combination treatment known as ECC-BYF III. The aim was to uncover whether NAC could provide significant therapeutic benefits alongside ECC-BYF III in improving mitochondrial function and overall respiratory health.
Over a period of eight weeks, the research focused on various aspects, including lung function, inflammation levels, and mitochondrial behavior in the mice. While we saw significant improvements in those treated with the ECC-BYF III combination, the isolated effects of NAC were less clear, resulting in a more complicated interpretation of its effectiveness alone in combating COPD.
Ultimately, our findings suggest that while NAC might play a role in a broader treatment strategy, it's particularly the combination with ECC-BYF III that demonstrates notable protective benefits against mitochondrial dysfunction in COPD mice. This study enriches our understanding of how various treatments can work together for better health outcomes in individuals suffering from this debilitating condition.
Over a period of eight weeks, the research focused on various aspects, including lung function, inflammation levels, and mitochondrial behavior in the mice. While we saw significant improvements in those treated with the ECC-BYF III combination, the isolated effects of NAC were less clear, resulting in a more complicated interpretation of its effectiveness alone in combating COPD.
Ultimately, our findings suggest that while NAC might play a role in a broader treatment strategy, it's particularly the combination with ECC-BYF III that demonstrates notable protective benefits against mitochondrial dysfunction in COPD mice. This study enriches our understanding of how various treatments can work together for better health outcomes in individuals suffering from this debilitating condition.
Most Useful Reviews
7.5
Avoids Exacerbations
1 people found this helpful
I have been using this NAC for several years and remain satisfied. It is a cost-effective analogue to pharmaceutical preparations containing the same active ingredient. NAC proves useful for chronic obstructive pulmonary disease, acting on the bronchial tube lining. I take it during winter at a dosage of 1000-1200 mg daily to prevent severe exacerbations of the disease, especially in an elderly relative with Parkinson's disease.
8
Improves Lung Function
NAC possesses antioxidant and expectorant properties, improving lung function, reducing mucus, and facilitating its expulsion from the lungs. It alleviates symptoms of bronchitis and chronic obstructive pulmonary disease. Additionally, it participates in the synthesis of glutathione and regulates glutamate levels.
7.5
Helpful for COPD
8 people found this helpful
This is not my first purchase of NAC, as it is a cost-effective alternative to pharmaceutical products with the same active ingredient. NAC is beneficial for chronic obstructive pulmonary disease, aiding antioxidant processes in the brain due to its role as a precursor to glutathione. I highly recommend buying this product.
Medical Researches
SCIENTIFIC SCORE
Possibly Effective
Based on 4 Researches
7.5
- All Researches
9
We examined how N-acetyl-L-cysteine (NAC) impacts lung health in the context of chronic obstructive pulmonary disease (COPD) by exposing rats to cigarette smoke (CS) over a four-week period. This study set up a model of lung injury to assess the damage caused by CS and the protective effects of NAC.
After exposure, we observed significant changes in the lung tissue, including widening of the alveolar walls and increased inflammatory cell infiltration, suggesting serious oxidative injury. We found that NAC treatment helped counteract some of the harmful effects, reducing markers of oxidative stress like malondialdehyde while boosting protective enzymes such as superoxide dismutase.
Additionally, we noted that in lung cells exposed to cigarette smoke, NAC also mitigated apoptosis, which is a form of programmed cell death induced by oxidative stress. This underscores the potential for NAC as a therapeutic agent to replenish the body’s glutathione and aid in protecting lung health amidst the damaging effects of smoking.
Overall, our findings point to NAC's beneficial role in shielding lung tissues from damage due to cigarette smoke, reinforcing its use as an antioxidant in managing COPD.
After exposure, we observed significant changes in the lung tissue, including widening of the alveolar walls and increased inflammatory cell infiltration, suggesting serious oxidative injury. We found that NAC treatment helped counteract some of the harmful effects, reducing markers of oxidative stress like malondialdehyde while boosting protective enzymes such as superoxide dismutase.
Additionally, we noted that in lung cells exposed to cigarette smoke, NAC also mitigated apoptosis, which is a form of programmed cell death induced by oxidative stress. This underscores the potential for NAC as a therapeutic agent to replenish the body’s glutathione and aid in protecting lung health amidst the damaging effects of smoking.
Overall, our findings point to NAC's beneficial role in shielding lung tissues from damage due to cigarette smoke, reinforcing its use as an antioxidant in managing COPD.
7
We set out to understand the impact of N-acetyl-L-cysteine (NAC) on chronic obstructive pulmonary disease (COPD) by examining its effects in a study involving COPD mice. These mice were divided into groups, where some received NAC while others were given a combination treatment known as ECC-BYF III. The aim was to uncover whether NAC could provide significant therapeutic benefits alongside ECC-BYF III in improving mitochondrial function and overall respiratory health.
Over a period of eight weeks, the research focused on various aspects, including lung function, inflammation levels, and mitochondrial behavior in the mice. While we saw significant improvements in those treated with the ECC-BYF III combination, the isolated effects of NAC were less clear, resulting in a more complicated interpretation of its effectiveness alone in combating COPD.
Ultimately, our findings suggest that while NAC might play a role in a broader treatment strategy, it's particularly the combination with ECC-BYF III that demonstrates notable protective benefits against mitochondrial dysfunction in COPD mice. This study enriches our understanding of how various treatments can work together for better health outcomes in individuals suffering from this debilitating condition.
Over a period of eight weeks, the research focused on various aspects, including lung function, inflammation levels, and mitochondrial behavior in the mice. While we saw significant improvements in those treated with the ECC-BYF III combination, the isolated effects of NAC were less clear, resulting in a more complicated interpretation of its effectiveness alone in combating COPD.
Ultimately, our findings suggest that while NAC might play a role in a broader treatment strategy, it's particularly the combination with ECC-BYF III that demonstrates notable protective benefits against mitochondrial dysfunction in COPD mice. This study enriches our understanding of how various treatments can work together for better health outcomes in individuals suffering from this debilitating condition.
7
We explored the role of mucus hypersecretion in chronic obstructive pulmonary disease (COPD), which is a common trait tied to worse health outcomes. Notably, this mucus issue can sometimes arise before any noticeable airway obstruction, prompting us to consider early interventions as a way to prevent further complications.
Our review delved into the effectiveness of N-acetylcysteine (NAC), a treatment that shows promise in improving mucus clearance and reducing harmful protein expressions related to mucus. NAC operates through antioxidant mechanisms, both directly and indirectly, and it intervenes in inflammation by targeting specific pathways in airway cells. It helps inhibit certain factors responsible for inflammation and can lower levels of certain harmful cytokines.
Through various clinical experiences, it appears that using NAC as an add-on therapy can help alleviate symptoms and enhance the overall well-being of COPD patients. Thus, we conclude that NAC may serve as a worthy candidate for the early treatment of individuals at risk of developing COPD.
Our review delved into the effectiveness of N-acetylcysteine (NAC), a treatment that shows promise in improving mucus clearance and reducing harmful protein expressions related to mucus. NAC operates through antioxidant mechanisms, both directly and indirectly, and it intervenes in inflammation by targeting specific pathways in airway cells. It helps inhibit certain factors responsible for inflammation and can lower levels of certain harmful cytokines.
Through various clinical experiences, it appears that using NAC as an add-on therapy can help alleviate symptoms and enhance the overall well-being of COPD patients. Thus, we conclude that NAC may serve as a worthy candidate for the early treatment of individuals at risk of developing COPD.
7
NAC restores ECM proteins effectively
We explored how n-acetyl-l-cysteine (NAC) affects human lung fibroblasts (hLFs) when exposed to cigarette smoke extract (CSE), which is known to contribute to chronic obstructive pulmonary disease (COPD). In our investigation, we discovered that CSE activates certain caspases and promotes oxidative stress within the cells, leading to decreased levels of important extracellular matrix proteins such as collagen Iα1 and fibronectin.
Importantly, we observed that treating the lung fibroblasts with NAC helped counteract these negative effects. NAC was effective in reducing oxidative stress, thereby inhibiting the activation of caspases that contribute to the degradation of the extracellular matrix. This restoration of collagen and fibronectin levels suggests a potential positive role for NAC in maintaining lung tissue integrity during cigarette smoke exposure.
Our findings support the notion that NAC could be a valuable therapeutic approach in mitigating some of the damaging effects associated with smoking-related lung diseases. While further research is warranted to fully understand the implications, we believe that targeting oxidative stress with NAC could offer a hopeful pathway for improving outcomes in individuals suffering from COPD.
Importantly, we observed that treating the lung fibroblasts with NAC helped counteract these negative effects. NAC was effective in reducing oxidative stress, thereby inhibiting the activation of caspases that contribute to the degradation of the extracellular matrix. This restoration of collagen and fibronectin levels suggests a potential positive role for NAC in maintaining lung tissue integrity during cigarette smoke exposure.
Our findings support the notion that NAC could be a valuable therapeutic approach in mitigating some of the damaging effects associated with smoking-related lung diseases. While further research is warranted to fully understand the implications, we believe that targeting oxidative stress with NAC could offer a hopeful pathway for improving outcomes in individuals suffering from COPD.
User Reviews
USERS' SCORE
Good
Based on 4 Reviews
8.2
- All Reviews
- Positive Reviews
- Negative Reviews
7.5
Avoids Exacerbations
1 people found this helpful
I have been using this NAC for several years and remain satisfied. It is a cost-effective analogue to pharmaceutical preparations containing the same active ingredient. NAC proves useful for chronic obstructive pulmonary disease, acting on the bronchial tube lining. I take it during winter at a dosage of 1000-1200 mg daily to prevent severe exacerbations of the disease, especially in an elderly relative with Parkinson's disease.
8
Improves Lung Function
NAC possesses antioxidant and expectorant properties, improving lung function, reducing mucus, and facilitating its expulsion from the lungs. It alleviates symptoms of bronchitis and chronic obstructive pulmonary disease. Additionally, it participates in the synthesis of glutathione and regulates glutamate levels.
7.5
Helpful for COPD
8 people found this helpful
This is not my first purchase of NAC, as it is a cost-effective alternative to pharmaceutical products with the same active ingredient. NAC is beneficial for chronic obstructive pulmonary disease, aiding antioxidant processes in the brain due to its role as a precursor to glutathione. I highly recommend buying this product.
7.5
Mucus Relief
NAC is beneficial for all lung and respiratory diseases, especially chronic bronchitis and chronic obstructive pulmonary disease. It is believed to assist with acute respiratory diseases and emphysema. Initially, I observed that mucus was being expelled from the lungs, bronchi, and nose. Overall, I am satisfied with the results from this dietary supplement.
Frequently Asked Questions
7.5
Mucus Relief
NAC is beneficial for all lung and respiratory diseases, especially chronic bronchitis and chronic obstructive pulmonary disease. It is believed to assist with acute respiratory diseases and emphysema. Initially, I observed that mucus was being expelled from the lungs, bronchi, and nose. Overall, I am satisfied with the results from this dietary supplement.
7.5
Avoids Exacerbations
1 people found this helpful
I have been using this NAC for several years and remain satisfied. It is a cost-effective analogue to pharmaceutical preparations containing the same active ingredient. NAC proves useful for chronic obstructive pulmonary disease, acting on the bronchial tube lining. I take it during winter at a dosage of 1000-1200 mg daily to prevent severe exacerbations of the disease, especially in an elderly relative with Parkinson's disease.
8
Improves Lung Function
NAC possesses antioxidant and expectorant properties, improving lung function, reducing mucus, and facilitating its expulsion from the lungs. It alleviates symptoms of bronchitis and chronic obstructive pulmonary disease. Additionally, it participates in the synthesis of glutathione and regulates glutamate levels.
7.5
Helpful for COPD
8 people found this helpful
This is not my first purchase of NAC, as it is a cost-effective alternative to pharmaceutical products with the same active ingredient. NAC is beneficial for chronic obstructive pulmonary disease, aiding antioxidant processes in the brain due to its role as a precursor to glutathione. I highly recommend buying this product.
9
We examined how N-acetyl-L-cysteine (NAC) impacts lung health in the context of chronic obstructive pulmonary disease (COPD) by exposing rats to cigarette smoke (CS) over a four-week period. This study set up a model of lung injury to assess the damage caused by CS and the protective effects of NAC.
After exposure, we observed significant changes in the lung tissue, including widening of the alveolar walls and increased inflammatory cell infiltration, suggesting serious oxidative injury. We found that NAC treatment helped counteract some of the harmful effects, reducing markers of oxidative stress like malondialdehyde while boosting protective enzymes such as superoxide dismutase.
Additionally, we noted that in lung cells exposed to cigarette smoke, NAC also mitigated apoptosis, which is a form of programmed cell death induced by oxidative stress. This underscores the potential for NAC as a therapeutic agent to replenish the body’s glutathione and aid in protecting lung health amidst the damaging effects of smoking.
Overall, our findings point to NAC's beneficial role in shielding lung tissues from damage due to cigarette smoke, reinforcing its use as an antioxidant in managing COPD.
After exposure, we observed significant changes in the lung tissue, including widening of the alveolar walls and increased inflammatory cell infiltration, suggesting serious oxidative injury. We found that NAC treatment helped counteract some of the harmful effects, reducing markers of oxidative stress like malondialdehyde while boosting protective enzymes such as superoxide dismutase.
Additionally, we noted that in lung cells exposed to cigarette smoke, NAC also mitigated apoptosis, which is a form of programmed cell death induced by oxidative stress. This underscores the potential for NAC as a therapeutic agent to replenish the body’s glutathione and aid in protecting lung health amidst the damaging effects of smoking.
Overall, our findings point to NAC's beneficial role in shielding lung tissues from damage due to cigarette smoke, reinforcing its use as an antioxidant in managing COPD.
7
We explored the role of mucus hypersecretion in chronic obstructive pulmonary disease (COPD), which is a common trait tied to worse health outcomes. Notably, this mucus issue can sometimes arise before any noticeable airway obstruction, prompting us to consider early interventions as a way to prevent further complications.
Our review delved into the effectiveness of N-acetylcysteine (NAC), a treatment that shows promise in improving mucus clearance and reducing harmful protein expressions related to mucus. NAC operates through antioxidant mechanisms, both directly and indirectly, and it intervenes in inflammation by targeting specific pathways in airway cells. It helps inhibit certain factors responsible for inflammation and can lower levels of certain harmful cytokines.
Through various clinical experiences, it appears that using NAC as an add-on therapy can help alleviate symptoms and enhance the overall well-being of COPD patients. Thus, we conclude that NAC may serve as a worthy candidate for the early treatment of individuals at risk of developing COPD.
Our review delved into the effectiveness of N-acetylcysteine (NAC), a treatment that shows promise in improving mucus clearance and reducing harmful protein expressions related to mucus. NAC operates through antioxidant mechanisms, both directly and indirectly, and it intervenes in inflammation by targeting specific pathways in airway cells. It helps inhibit certain factors responsible for inflammation and can lower levels of certain harmful cytokines.
Through various clinical experiences, it appears that using NAC as an add-on therapy can help alleviate symptoms and enhance the overall well-being of COPD patients. Thus, we conclude that NAC may serve as a worthy candidate for the early treatment of individuals at risk of developing COPD.
7
We set out to understand the impact of N-acetyl-L-cysteine (NAC) on chronic obstructive pulmonary disease (COPD) by examining its effects in a study involving COPD mice. These mice were divided into groups, where some received NAC while others were given a combination treatment known as ECC-BYF III. The aim was to uncover whether NAC could provide significant therapeutic benefits alongside ECC-BYF III in improving mitochondrial function and overall respiratory health.
Over a period of eight weeks, the research focused on various aspects, including lung function, inflammation levels, and mitochondrial behavior in the mice. While we saw significant improvements in those treated with the ECC-BYF III combination, the isolated effects of NAC were less clear, resulting in a more complicated interpretation of its effectiveness alone in combating COPD.
Ultimately, our findings suggest that while NAC might play a role in a broader treatment strategy, it's particularly the combination with ECC-BYF III that demonstrates notable protective benefits against mitochondrial dysfunction in COPD mice. This study enriches our understanding of how various treatments can work together for better health outcomes in individuals suffering from this debilitating condition.
Over a period of eight weeks, the research focused on various aspects, including lung function, inflammation levels, and mitochondrial behavior in the mice. While we saw significant improvements in those treated with the ECC-BYF III combination, the isolated effects of NAC were less clear, resulting in a more complicated interpretation of its effectiveness alone in combating COPD.
Ultimately, our findings suggest that while NAC might play a role in a broader treatment strategy, it's particularly the combination with ECC-BYF III that demonstrates notable protective benefits against mitochondrial dysfunction in COPD mice. This study enriches our understanding of how various treatments can work together for better health outcomes in individuals suffering from this debilitating condition.
References
- Chen J, Cheng Y, Cui H, Li S, Duan L, et al. N‑acetyl‑L‑cysteine protects rat lungs and RLE‑6TN cells from cigarette smoke‑induced oxidative stress. Mol Med Rep. 2025;31. doi:10.3892/mmr.2025.13462
- Song M, Han M, Zhang H, Yang Y, Tian Y, et al. The Effective Compound Combination of Bufei Yishen Formula III Improves the Mitochondrial Dysfunction via Inhibiting JNK/Sab Pathway in COPD Mice. Drug Des Devel Ther. 2025;19:525. doi:10.2147/DDDT.S487074
- Baraldi F, Bigoni T, Foschino Barbaro MP, Micheletto C, Scioscia G, et al. Mucus production and chronic obstructive pulmonary disease, a possible treatment target: zooming in on N-acetylcysteine. Monaldi Arch Chest Dis. 2025. doi:10.4081/monaldi.2025.3159
- La Mensa A, Buscetta M, Woldhuis RR, Cimino M, Giuffrè MR, et al. Caspase inhibition restores collagen Iα1 and fibronectin release in cigarette smoke extract-exposed human lung fibroblasts. Am J Physiol Lung Cell Mol Physiol. 2025;328:L239. doi:10.1152/ajplung.00214.2024
